DTAB: Drugs Technical Advisory Board reconstituted: Detail here

The reconstitution of the DTAB operates within the framework of the Drugs and Cosmetics Act, 1940.

March 13, 2025

252

DTAB: Drugs Technical Advisory Board reconstituted: Detail here

Table of Contents

Last Updated on March 21, 2025 by The Health Master

DTAB

The Ministry of Health and Family Welfare has just reconstituted the Drugs Technical Advisory Board (DTAB) vide notification No. S.O. 1159(E) dated 12-03-2025.

Download the notification No. S.O. 1159(E) dated 12-03-2025

This is an important step towards how the nation will approach drug safety and efficacy.

Follow us on WhtasApp Channel

A Look at the Constitution

The recent notification, dated March 12th, marks a pivotal moment, replacing the 18-member committee that had been in place since October 18, 2021.

Previously, the DTAB was reconstituted in May 2018.

The core structure remains, with the Director General of Health Services, New Delhi, serving as the ex-officio chairman.

However, the changes have been made by the inclusion of new state drug regulators and industry representatives.

Read and Download Minutes of all meetings of DTAB

Key Additions

State drug regulators from Goa and Himachal Pradesh have been included in place of state regulators from Gujarat and Madhya Pradesh.

Other key figures have been included from the Indian Pharmaceutical Alliance (IP Alliance) and the Indian Pharmaceutical Association.

State Collaboration:

The inclusion of state regulators from Goa and Himachal Pradesh will add their regional expertise.

Industry Collaboration:

The addition of representatives from the Indian Pharmaceutical Alliance and the Indian Pharmaceutical Association will increase the importance of industry input.

The reconstituted board is as under:

Ex-Officio Members:

Director General of Health Services, New Delhi (Chairman)
Drugs Controller General of India (DCGI)

Directors of:

Central Drugs Laboratory, Kolkata;
Central Research Institute, Kassauli;
Indian Veterinary Research Institute, Bareilly; and
Central Drugs Research Institute, Lucknow.

Chairman of the National Medical Commission (NMC)
President of the Pharmacy Council of India (PCI)

New Additions:

Director, Directorate of Food and Drug Administration, Goa
State Drugs Controller, Drugs Control Administration, Himachal Pradesh
Government analyst, Drug Control Laboratory, Andhra Pradesh
Government analyst, Government Public Analyst Laboratory, Uttar Pradesh
Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IP Alliance)
Dr. R. N. Gupta, National President, Indian Pharmaceutical Association
Atul Kumar Nasa, member, executive committee, Pharmacy Council of India
Dr Bhavesh Vyas, Assistant Professor, Department of Pharmacology, Narendra Modi Medical College, Ahmedabad.

Continuing Members:

Dr. Vijay Oza, Member, Post Graduate Medical Education Board, National Medical Commission
Dr. Jerin Jose Cherian, Scientist-E, Indian Council of Medical Research

Legal Framework: The Drugs and Cosmetics Act, 1940

The reconstitution of the DTAB operates within the framework of the Drugs and Cosmetics Act, 1940.

According to Section 5 of this act, nominated and elected members serve for three years and are eligible for re-nomination or re-election, provided they maintain their original office.

The board also has the authority to create subcommittees and appoint external experts for specific matters.

Operational Efficiency: Quorum and Procedures

To ensure efficient operations, the board, with the central government’s approval, can establish bylaws to determine quorum and regulate its procedures.

This flexibility allows the board to adapt to changing circumstances and address emerging issues promptly.

List of DTAB members as per notification:

Serial Number.	Name/Official designation of the Member.	Status in Drugs Technical Advisory Board.	Section of the Drugs and Cosmetics Act, 1940 under which appointed, nominated or elected.
(1)	(2)	(3)	(4)
1.	The Director General of Health Services, New Delhi.	Chairman ex- officio	Appointed under clause (i) of sub section (2) of section 5 of the Act.
2.	The Drugs Controller, India, New Delhi.	Member ex- officio	Appointed under clause (ii) of sub section (2) of section 5 of the Act.
3.	The Director, Central Drugs Laboratory, Kolkata.	Member ex- officio	Appointed under clause (iii) of sub section (2) section 5 of the Act.
4.	The Director, Central Research Institute, Kasauli.	Member ex- officio	Appointed under clause (iv) of sub section (2) section 5 of the Act.
5.	The Director, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh.	Member ex- officio	Appointed under clause (v) of sub section (2) section 5 of the Act.
6.	The Chairman, National Medical Commission, India.	Member ex- officio	Appointed under clause (vi) of sub section (2) section 5 of the Act.
7.	The President, Pharmacy Council of India.	Member ex- officio	Appointed under clause (vii) of sub section (2) section 5 of the Act.
8.	The Director, Central Drugs Research Institute, Lucknow.	Member ex- officio	Appointed under clause (viii) of sub section (2) section 5 of the Act.
9.	Director, Directorate of Food and Drugs Administration, Goa.	Member	Nominated under clause (ix) of sub section (2) section 5 of the Act.
10.	State Drugs Controller, Drugs Control Administration, Himachal Pradesh.	Member	Nominated under clause (ix) of sub section (2) section 5 of the Act.
11.	Dr. Atul Kumar Nasa, Member, Executive Committee, Pharmacy Council of India.	Member	Elected under clause (x) of sub section (2) section 5 of the Act.
12.	Dr. Vijay Oza, Member, Post Graduate Medical Education Board, National Medical Commission.	Member	Elected under clause (xi) of sub section (2) section 5 of the Act.
13.	Shri Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance.	Member	Nominated under clause (xii) of sub section (2) of section 5 of the Act.
14.	Dr. Jerin Jose Cherian, Scientist- E, Indian Council of Medical Research.	Member	Elected under clause (xiii) of sub section (2) of section 5 of the Act.
15.	Dr. Bhavesh Vyas, Assistant Professor, Department of Pharmacology, Narendra Modi Medical College, Ahmedabad, Gujarat.	Member	Elected under clause (xiv) of sub section (2) of section 5 of the Act.
16.	Dr. R.N. Gupta, National President, Indian Pharmaceutical Association.	Member	Elected under clause (xv) of sub section (2) of section 5 of the Act.
17.	Government Analyst, Drugs Control Laboratory, Vijayawada, Andhra Pradesh.	Member	Nominated under clause (xvi) of sub section (2) of section 5 of the Act.
18.	Government Analyst, Government Public Analyst Laboratory, Lucknow, Uttar Pradesh.	Member	Nominated under clause (xvi) of sub section (2) of section 5 of the Act.

Also read following FAQs

Q: What is the primary role of the Drugs Technical Advisory Board (DTAB)?

A: The DTAB advises the Central Government and State Governments on technical matters related to drugs and cosmetics, ensuring safety and efficacy.

Q: How often is the DTAB reconstituted?

A: The DTAB is reconstituted periodically, as deemed necessary by the Ministry of Health and Family Welfare, typically within three years of the previous board’s formation, as per the Drugs and Cosmetics Act 1940.

Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.

Also explore the various committees, click below links:

DCC

DTAB

Technical Committee

Hathi Committee

Mashelkar Committee

Must read

DTAB recommends key amendments of MDR, 2017

DTAB recommends Stricter Qualifications for Wholesale Drug Licenses

DTAB agrees with proposal to amend New Drugs and Clinical Trials Rules

DTAB recommends changes to New Drugs and Clinical Trials Rules

DTAB’s recommendations about tackling the Antimicrobial Resistance Crisis